The OAC has been made aware of a recent recommendation by the U.S. Food and Drug Administration (FDA) that the chronic weight management medication Belviq, Belviq XR (lorcaserin) should be removed from the U.S. market and all patients currently taking the medication should stop.
We recognize this news may be unsettling for individuals. The OAC encourages you to speak with your healthcare provider to discuss your overall weight management plan. If you do not currently have a healthcare provider, please visit ObesityCareProviders.com to locate one in your area.
If you are seeking more information on weight-loss options, please feel free to view the OAC’s Understanding Your Weight-loss Options Brochure by clicking here.
For any questions regarding the FDA’s recommendation or your current healthcare plan, please speak directly with your healthcare provider.
Leave a Reply
You must be logged in to post a comment.